Adapting the Tumor Board Model for Mental Illness and Cancer
Launched by MASSACHUSETTS GENERAL HOSPITAL · Apr 26, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to support patients who have both serious mental illnesses and a recent cancer diagnosis. Specifically, it tests a virtual tumor board, which is a group of doctors and mental health professionals who meet online to discuss and plan care for these patients. The goal is to see if this approach can improve patient care, help manage psychiatric symptoms, and boost the confidence of healthcare providers in treating these complex cases.
To participate in the trial, you need to be at least 18 years old, speak English well, and have a confirmed diagnosis of a serious mental illness like schizophrenia, bipolar disorder, or severe depression, along with a new diagnosis of certain types of cancer (like breast, lung, or gastrointestinal cancer). You also need to have seen a cancer specialist within the last two months. Participants will engage in the virtual meetings and will have their experiences and outcomes closely monitored throughout the study. This is an exciting opportunity to contribute to a better understanding of how to help individuals facing both mental health challenges and cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years old
- • 2. Verbal fluency in English
- • 3. SMI (schizophrenia spectrum disorder, bipolar disorder, or major depressive disorder with either prior psychiatric hospitalization, history of suicide attempt/suicidal ideation, Medicaid insurance, and/or comorbid alcohol or opioid use disorder) confirmed by diagnostic evaluation of study psychiatrist
- • 4. New invasive stage I-IV breast, lung, gastrointestinal, genitourinary, or head and neck cancer (highly suspected or confirmed according to documentation by the oncologist or pathology)
- • 5. Oncology consultation at or referral to a MGH Danvers within the past 8 weeks
- Exclusion Criteria:
- • 1. Have cognitive impairment severe enough to interfere with completing brief study assessments or providing informed consent and does not have a guardian who can provide consent
- • 2. Recurrence of same cancer type
- • 3. Do not have verbal fluency in English
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Danvers, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported